detected in genomic DNA isolated from blood cells of their parents, suggesting that the mutation is the consequence of germinal mosaicism in 1 progenitor. In functional studies, the GluN2A-A643D mutation increased the potency of the agonists L-glutamate and glycine and decreased the potency of endogenous negative modulators, including protons, magnesium and zinc but reduced agonist-evoked peak current response in mammalian cells, suggesting that this mutation has a mixed effect on N-methyl-D-aspartate receptor function. Conclusion: De novo GRIN2A mutations can give rise to a neurodevelopmental and movement disorder without epilepsy. V C 2018 International Parkinson and Movement Disorder Society K e y W ord s: Glutamate receptor; NMDA receptor; GRIN2A; GluN2A; movement disorder
The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic receptor that binds glutamate, the main excitatory neurotransmitter of the central nervous system. This receptor class plays important roles in development, synaptic plasticity, learning, and memory. 1 The NMDAR has a tetrameric structure, consisting of 2 GluN1 and 2 GluN2 subunits. The GluN1 subunit is encoded by the GRIN1 gene, whereas the GluN2 subunits are encoded by the genes GRIN2A, GRIN2B, GRIN2C, and GRIN2D, which have distinct spatial and temporal expression patterns. [2] [3] [4] [5] [6] Levels of GRIN2B and GRIN2D expression are high before birth and subsequently decline in most brain regions, whereas the expression of GRIN2A and GRIN2C increases after birth. 7 NMDARs are Ca 21 -permeable, voltage-dependent receptors that mediate a slow synaptic current and are blocked by extracellular magnesium. 8 The overactivation of NMDARs has been implicated in the induction of seizures and cell death, [9] [10] [11] [12] [13] whereas hypofunction of this receptor may contribute to schizophrenia. 14, 15 Alterations in GRIN2A were first described in 2010 16 in 3 patients carrying deletions in chromosome 16p13, including the GRIN2A gene. These patients were intellectually impaired, with dysmorphic features and epilepsy involving the rolandic region. Three subsequent studies described point mutations and deletions in GRIN2A in patients with epilepsy-aphasia spectrum and idiopathic focal epilepsies with centrotemporal spikes, particularly in those with more severe phenotypes. [17] [18] [19] Lesca and colleagues 17 detected de novo or inherited GRIN2A deletions or mutations in about 20% of cases of Landau-Kleffner syndrome, epilepsy with continuous spikes and waves during slow-wave sleep, and atypical benign partial epilepsy, often associated with speech impairment. Lemke and colleagues 18 reported genetic alterations in GRIN2A in 7.5% of idiopathic focal epilepsies patients studied and found that mutations were more common in more severe phenotypes: 4.9% (12/245) in benign epilepsy with centrotemporal spikes and 17.6% (9/51) in continuous spikes and waves during slow-wave sleep patients. Moreover, they detected exon-disrupting microdeletions of the GRIN2A gene in 1% (3/286) of individuals screened for copy number variations. Finally, Carvill and colleagues 19 identified GRIN2A mutations in 9% (4/44) of patients with epilepsy-aphasia spectrum. Alterations in GRIN2A have also been reported in patients with early-onset epileptic encephalopathy and severe developmental delay. 1, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] To date, whole-exome and genome sequencing have identified a substantial number of point mutations and deletions (>100) scattered across all domains of the GRIN2A gene. 1, 30, 31 The large number of mutations found in GRIN2A may reflect the postnatal increase in the expression of GluN2A, which prevents catastrophic preterm neurologic complications and allows patients to survive to full term, albeit with neurologic complications that appear later in life as GRIN2A expression increases.
------------------------------------------------------------------------------------------------------------------------------
Encephalopathies caused by mutations in genes encoding the other NMDAR subunits (GRIN1, GRIN2B, and GRIN2D) are considered part of a phenotypic spectrum that encompasses patients with a constellation of symptoms, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and movement disorders. 20, 26, [32] [33] [34] Here, we describe a neurodevelopmental and movement disorder without seizures in 2 siblings with the same GRIN2A mutation.
Methods

Consent and Approval
Research protocols were approved by the Ethics Committee of the Hospital Santiago de Compostela (Galicia, Spain), and families provided informed consent. All in vitro experiments were conducted in accordance with the guidelines of Emory University (Atlanta, Georgia).
Targeted Next-Generation Sequencing
Targeted enrichment was performed using an insolution hybridization technology (Sure Select XT; Agilent Technologies, Santa Clara, California), and the Miseq platform (Illumina, Santa Clara, California) was used for subsequent sequencing. One custom Sure Select probe library was designed to capture the exons and exon-intron-boundaries of 428 genes associated with neuropediatric diseases, including all corresponding transcripts. The Sure Design web-based probe design tool was used for this purpose (https://earray. chem.agilent.com/suredesign/). To ensure optimal representation of all regions of interest, we designed different subgroups of probes according to guanine-cytosine content and location with respect to repetitive sequences. Sequence capture, enrichment, and elution were performed according to the manufacturer's instructions. Captured fragments were sequenced in pair-end 100-base mode using the Miseq platform. Image analysis and processing of fluorescence intensity in sequences ("base calling") was performed using Real Time Analysis software v.1.8.70 (Illumina, Santa Clara, California), and the FastQC v0.10.1 program (http://www. bioinformatics.bbsrc.ac.uk/projects/fastqc/) was used for data quality control. Reads were aligned to the reference genome GRCh37 with BWA v0.7.9a. 35 NGSrich v0.7.5 software (http://ngsrich.sourceforge.net) was used as a control prior to variant detection, and BEDTools 2.17.0 (http://bedtools.readthedocs.org/en/latest/ #) and Picard 1.114 (http://picard.sourceforge.net) were used for the intermediate steps.
Mutagenesis and Electrophysiology Studies
Complementary DNAs (cDNAs) encoding the wildtype (WT) human NMDA receptor subunit GluN1-1a (hereafter GluN1; GenBank accession number NP_015566) and GluN2A (GenBank accession number NP_000824) were subcloned into pCI-neo mammalian expression vector (Promega, Madison, Wisconsin) to
express recombinant NMDARs. GluN2A-A643D was generated by site-directed mutagenesis using the QuikChange protocol (Stratagene, La Jolla, California). The mutagenesis product was confirmed by DNA sequencing (Eurofins, Louisville, Kentucky). Complementary RNAs (cRNAs) was synthesized in vitro and coinjected into Xenopus laevis oocytes (Ecocyte Bio Science, Austin, Texas) as previously described. 28 Two-electrode voltageclamp (TEVC) recordings from oocytes were performed at room temperature (23 8C) to measure NMDARmediated inward currents in response to stimulation with the coagonists glutamate and glycine. The recording solution contained (in mM) 90 NaCl (sodium chloride), 1 KCl (potassium chloride), 10 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.5 BaCl 2 (barium chloride), 0.01 EDTA (ethylenediaminetetraacetic acid) (23 8C, pH 7.4 unless otherwise stated). The membrane potential was held at 240 mV for all TEVC recordings unless otherwise stated. The agonist concentration-response data were fitted using equation 1:
where N is the Hill slope and EC 50 is the concentration of the agonist that produces a half-maximal effect. Experiments evaluating the sensitivity of the channel to extracellular zinc were performed in the presence of tricine (10 mM) at pH 7.3 (V HOLD , 220 mV). ZnCl 2 (zinc chloride) solutions (10 mM) were prepared fresh daily and added directly to the recording solution (with no EDTA) to obtain the desired nominal-free concentration of zinc. 36 Experiments evaluating the sensitivity of the channel to magnesium blockade were performed in the recording solution with no EDTA at a holding potential of 260 mV. Glutamate (100 lM) and glycine (100 lM) were used in all oocyte experiments unless otherwise stated. The concentration-response curves for magnesium and zinc inhibition were fitted using equation 2:
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where IC 50 is the concentration of the inhibitor that produces a half-maximal effect and minimum is the degree of residual response at a saturating concentration of the inhibitor. The whole-cell voltage clamp current recordings were performed on transiently transfected human embryonic kidney cells 293 (HEK293) (ATCC CRL-1573, Manassas, Virginia) with plasmid cDNAs encoding WT human GluN1/GluN2A or GluN1/GluN2A-A643D with a solution containing (in mM) 150 NaCl, 3 KCl, 10 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.01 EDTA, 1.0 CaCl 2 (calcium chloride), and 11 D-mannitol, with the pH adjusted to 7.4 by the addition of NaOH (sodium hydroxide) (23 8C). 28 The recording electrodes were prepared a vertical puller (Narishige P-10, Tokyo, Japan) using thin-walled filamented borosilicate glass (TW150F-4; World Precision Instruments, Sarasota, Florida) and filled with the internal solution (in mM: 110 Dgluconic acid, 110 CsOH (cesium hydroxide), 30 CsCl (cesium chloride), 5 HEPES, 4 NaCl, 0.5 CaCl 2 , 2 MgCl 2 , (magnesium chloride) 5 BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N,N 0 ,N 0 -tetraacetic acid), 2 Na 2 ATP (adenosine 5 0 -triphosphate disodium), 0.3 NaGTP (guanosine 5 0 -triphosphate sodium); pH 7.35 with 300-310 mOsmol/kg of the osmolality). The current responses to the saturated concentrations of glutamate (1000 lM) and glycine (100 lM) were recorded using an Axopatch 200B patch-clamp amplifier (Molecular Devices, Sunnyvale, California), with the holding potential of 260 mV at room temperature (23 8C) . The current responses were digitized at 20 kHz using a Digidata 1440A data acquisition system (Molecular Devices, Sunnyvale, California), filtered at 8 kHz (23 dB, 8-pole Bessel filter; Frequency Devices, Ottawa, Illinois), and normalized to cell capacitance.
All reagents were purchased from Sigma (unless otherwise stated). Data were expressed as the mean 6 standard error of the mean, and the statistical difference was determined by unpaired t-test using the log EC 50 and IC 50 values. Current amplitudes from transfected HEK293 cells were compared using Mann-Whitney test. Significance for all tests was set at P < .05.
Results
Case Report
Patient 1 is a boy (aged 8 years at the time of writing) born to nonconsanguineous, healthy parents at week 35 of gestation by vaginal delivery following an uneventful pregnancy. His birth weight and length were 2860 g and 48 cm, respectively, and his Apgar score was 9/10. He displayed retarded psychomotor development, with delayed acquisition of language and motor milestones (sitting at 19 months, walking at 20 months, 2-word phrases at 5 years, and 3-word phrases at 6-7 years). From the first months of life, he experienced generalized dystonic attacks and hypertonia predominantly affecting the lower limbs. Physical examination at 19 months revealed generalized dystonia with upper-limb predominance, fluctuating muscular tone with a predominant extensor pattern in the lower limbs, truncal hypotonia, positive bilateral plantar grip, and an intense bilateral Galant reflex, and a diagnosis of dystonic cerebral palsy was established. A complete metabolic study of blood, urine, and cerebrospinal fluid including a screening for glucose transporter type 1 deficiency yielded normal results.
Magnetic resonance imaging (MRI) with spectroscopy, auditory and visual evoked potentials, and videoelectroencephalogram (EEG) revealed no findings of relevance. The patient exhibited convergent strabismus and hypermetropia, which were treated with botulinum toxin and corrective lenses as well as insomnia with frequent awakenings. In addition, the patient has obstructive sleep apnea syndrome, which required adenoidectomy and continuous positive airway pressure for 1 year, and makes a near continuous snoringlike breathing noise while awake, although for reasons unknown this is absent during sleep. Cognitive symptoms include moderate intellectual disability, reduced vocabulary, and difficulties using expressive language. The patient has never experienced a seizure, and repeated EEG recordings have revealed an absence of epileptiform abnormalities. Recent physical examinations detected dystonic movements and postures of the head, neck, trunk, and upper limbs (right predominance), severe problems in fine motor coordination, and an altered gait with dystonic postures.
At 6 years of age, to establish a diagnosis, targeted next-generation sequencing analysis of a panel of 428 genes associated with neuropediatric diseases was performed. The heterozygous variant c.C1928A, which promotes the amino-acid change p.Ala643Asp, was identified in exon 10 of the GRIN2A gene (reference sequence NM_000833.3). This variant was not registered in the 1000 Genomes Project database, the Single Nucleotide Polymorphism database, or the gnomAD database curated by the Broad Institute, 37 nor has it been detected in 400 chromosomes analyzed in a Spanish population (Fern andez-Marmiesse et al., unpublished data). An in silico pathogenicity assessment performed with CONDEL software 38 predicted that this variant was deleterious. The variant was not present in either parent.
Patient 2 (aged 4 years at the time of writing) is the younger sister of Patient 1 and was born at week 37 of gestation via vaginal delivery. The pregnancy was complicated by preterm labor from week 30. The patient's birth weight and length were 3430 g and 50 cm, respectively, and her Apgar score was 9/10. Similar to her brother, her psychomotor development was retarded with delayed acquisition of language and motor milestones (walking at 20 months, first words at 17 months, and 2-word phrases at 25 months). At 2 years of age, physical examination revealed mild dystonia of the upper limbs, dyskinesic movements, intentional and postural tremor, and major difficulties in fine manipulation, apraxic gait, and lack of motor coordination. In addition, she presented convergent strabismus, which was treated with lens occlusion, as 
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well as sleep disturbances and the same breathing noise as her brother. Blood tests and MRI with spectroscopy revealed no findings of note, and EEG results were normal across multiple tests. Currently, she displays mild cognitive impairment, occasionally omitting words, repeating 2-word phrases, and displaying serious difficulties in articulation, but has better verbal comprehension abilities than her brother. A genetic study using cycle sequencing after PCR (polymerase chain reaction) amplification of exon 10 of the GRIN2A gene revealed that patient 2 carries the same Ala643Asp variant as her brother. Because this variant is not present in the genomes of either parent but is present in 2 children born at different times, we conclude that it is the result of germline mosaicism of 1 of the parents (Fig. 1A) .
The alanine residue at position 643 in GluN2A lies in the M3 transmembrane domain helix, immediately before the conserved SYTANLAAF motif, which is critically important for normal channel function. This alanine is highly conserved across vertebrate species and other GluN subunits (Fig. 1B,C) .
Functional Studies
To examine the functional effects of the A643D variant, site-directed mutagenesis was used to introduce p.Ala643Asp into human WT GluN2A cDNA. The expression of GluN1/GluN2A-A643D in Xenopus laevis oocytes allowed the functional evaluation of mutant and WT NMDARs using TEVC current recordings, as previously described. 28 We first evaluated the effects of the mutation on the potency of the coagonists L-glutamate and glycine. Analysis of concentration-response relationships ( Fig. 2A,B) showed that GluN2A-A643D increased glutamate potency by 5-fold (EC 50 , 1.0 mM vs 5.0 mM for WT receptors; P < .0001, unpaired t-test) and increased glycine potency by 10-fold (EC 50 , 0.11 mM vs 1.1 mM for 
WT receptors; P < .0001, unpaired t-test; Fig. 2C,D ; Table 1 ). These data suggest that NMDARs carrying the GluN1/GluN2A-A643D mutation can be activated by a lower concentration of agonist than WT receptors. It is well known that NMDAR function can be negatively regulated by a number of endogenous negative modulators, including magnesium, protons, and zinc. 8 Using TEVC, we evaluated the effects of the mutation of on magnesium inhibition of NMDAR function in oocytes. Concentration-response data revealed a 2-fold reduction in the potency of magnesium in mutant NMDARs (IC 50 , 39 mM vs 19 mM for WT receptors; P 5 .004, unpaired t-test; Fig. 3A ; Table 1 ). We subsequently evaluated the effects of GluN2A-A643D on sensitivity to extracellular protons and zinc. GluN2A-A643D reduced sensitivity to zinc by 3-fold (IC 50 , 30 nM vs 9.1 nM for WT receptors; P 5 .007, unpaired t-test), and more than doubled the residual current measured in the presence of a saturating concentration (300 nM) of zinc (67% vs 31% residual current for WT receptors; P < .0001, unpaired t-test; Fig. 3B ; Table 1 ).
We further analyzed the effects of GluN2A-A643D on proton sensitivity by measuring current amplitude at pH 6.8 versus pH 7.6. The decrease in current amplitude at pH 6.8 versus pH 7.6 was slightly reduced in mutant receptors (48%) than WT receptors (43%; Fig.  3C ; Table 1 ), suggesting that tonic proton inhibition may be reduced in the mutant receptors.
We then measured and compared the current response of the mutant GluN2A-A643D to the WT receptors from transiently transfected HEK293 cells. Surprisingly, the mutant showed a significantly decreased peak current amplitude to a maximal concentration of agonists when coexpressed with the GluN1 subunit (GluN1/GluN2A-A643D: 52 6 19 pA/pF, n 5 15 vs WT GluN1/GluN2A: 167 6 29 pA/pF, n 5 8; P 5 .004, Mann-Whitney test; Fig. 4A,B) . Taken together, our electrophysiological data suggest a mixed effects of this potation on NMDAR function, including an increased receptor activation in response to low concentrations of agonist and the attenuated inhibitory effect of endogenous inhibitors (magnesium, protons, and zinc), but a decreased agonist-evoked current amplitude.
Discussion
Although GRIN2A mutations have been associated with a wide spectrum of neurodevelopmental disorders, including speech disorder without epilepsy in families with epilepsy-aphasia spectrum, 39 schizophrenia, 40 autism spectrum disorders, 40, 41 and intellectual disability, 42 mutations in this gene have not to date been implicated in movement disorders, in contrast to mutations in GRIN1 and GRIN2B. 32, 33 Encephalopathies caused by GRIN1 and GRIN2B mutations share common features: they are characterized by developmental delay, intellectual disability, autism spectrum disorder, hypotonia, spasticity, epilepsy, hyperkinetic movement disorders (dystonia, dyskinetic movements, and/or chorea), sleep disturbances, cortical visual 
impairment, and cerebral atrophy. The clinical presentations of patients 1 and 2 share some features with the phenotypes associated with GRIN1 and GRIN2B mutations, but with a less severe clinical course and without epilepsy, which is a component of all GRINassociated phenotypes to date. However, both siblings present with movement disorders (predominantly with dystonia, but also with motor coordination disorder, dysmetria, and tremor), sleep disturbances, abnormal breathing noise, and impaired ocular motility. An association between a GRIN2A mutation and anti-NMDAR encephalitis has been proposed. 43 Both clinical entities present with epilepsy and are similar in terms of seizure semiology and origination as well as language impairment. Two other features of anti-NMDAR encephalitis, movement disorder and sleep disturbances, are also present in both patients. 43 The p.Ala643Asp GluN2A variant is a nonconservative amino-acid substitution that likely affects secondary protein structure, as these residues differ in polarity, charge, size, and other properties. Moreover, in silico analysis predicts that this variant is probably deleterious to protein structure/function. This substitution is located in the M3 transmembrane domain of the ionotropic glutamate receptor family, a region devoid of variation in the healthy population. 44 This position is highly conserved across species, and reports have linked missense mutations in nearby residues (L649V, F652V) with GRIN2A-related disorders. Although the de novo mutation L649V has been identified in a patient with severe intellectual disability, dysplastic corpus callosum, delayed myelination, epilepsy, severe feeding problems, hypothyroidism, and mild facial dysmorphism, functional analyses have not been performed in the patient in question. 42 The F652V variant has been detected in a patient with continuous spikes and waves during slowwave sleep. 17 Coexpression of GluN1 with WT GluN2A or GluN2A-F652V generates functional NMDA receptors, as demonstrated using single-channel recordings in cell-attached patches with altered single-channel properties, 17 further supporting the functional importance of the protein region in which the A643 residue lies.
Further studies will be necessary to determine why mild encephalopathy with dystonia, with no epileptic abnormalities, is the primary clinical feature of our patients. Our functional analysis of the GluN2A-A643D variant indicates a mixed effect on NMDAR function. More in-depth studies (ie, in vivo study on transgenic animals) are required to elucidate the molecular mechanism underlying these patients' phenotypes.
Conclusions
Our findings expand the phenotypic spectrum of GRIN2A-related disorders to include neurodevelopmental and movement disorder (dystonia) without seizures. The data reported here reinforce the association between GRIN2A mutations and speech development and/or cognitive impairment, and emphasize the importance of molecular analyses not only for genetic counseling purposes but also for the identification of potential treatments.
